Novartis takes aim at MS blockbuster Tysabri in US and Europe
pharmaphorum
JULY 26, 2022
The looming competition piles further pressure on Biogen, whose MS franchise is already beset by generic competition to oral therapy Tecfidera (dimethyl glutamate), while its attempt to build a market for Alzheimer’s therapy Aduhelm (aducanumab) has ended in failure.
Let's personalize your content